Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma, and in the treatment of allergic rhinitis.
Montelukast is not anticipated to alter the metabolism of drugs metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, repaglinide). Concurrent use of gemfibrozil and montelukast may result in elevated montelukast plasma concentrations montelukast.
Concurrent use of prednisone and montelukast may result in severe peripheral edema.
Concurrent use of montelukast and repaglinide may result in increased repaglinide plasma concentrations.
Montelukast is metabolised by CYP 3A4, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, such as phenytoin, phenobarbital and rifampicin.
Concurrent use of montelukast and phenobarbital may result in decreased bioavailability of montelukast.
Concurrent use of montelukast and rifampin may result in decreased bioavailability of montelukast.